1
Clinical Trials associated with TB-500 (Thymosin Beta 4 17-23 Fragment)A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Sequential Dose-Escalation Study of TB-500 (Thymosin Beta 4 17-23 Fragment) in Adults With Stable Atherosclerotic Cardiovascular Disease to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Cardiovascular Biomarkers
This fictional study is an example of a ClinicalTrials.gov-style record. It describes a Phase 1/2 trial evaluating the safety and tolerability of TB-500 (a 17-23 fragment of thymosin beta 4) versus placebo in adults with stable atherosclerotic cardiovascular disease (ASCVD). Exploratory endpoints assess vascular function and inflammation biomarkers
100 Clinical Results associated with TB-500 (Thymosin Beta 4 17-23 Fragment)
100 Translational Medicine associated with TB-500 (Thymosin Beta 4 17-23 Fragment)
100 Patents (Medical) associated with TB-500 (Thymosin Beta 4 17-23 Fragment)
100 Deals associated with TB-500 (Thymosin Beta 4 17-23 Fragment)